{{.infobox .infobox-gene}}
| Symbol | MSTO1 |
| Full Name | Miosin |
| Chromosome | 1q22 |
| NCBI Gene ID | 55106 |
| OMIM | 604278 |
| Ensembl ID | ENSG00000135604 |
| UniProt ID | Q9BVI4 |
| Aliases | MSTO1, C8orf61 |
| Associated Diseases | PD, HSP, ALS, mitochondrial disorders |
MSTO1 (miosin) encodes a mitochondrial matrix protein that plays critical roles in regulating mitochondrial morphology, distribution, and quality control[1]. Originally identified as a novel protein with unknown function, MSTO1 has emerged as an important regulator of mitochondrial dynamics—a process fundamental to neuronal survival and function. Dysregulation of mitochondrial dynamics is a central feature of numerous neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS)[2][3].
MSTO1 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
The MSTO1 gene is located on chromosome 1q22 and consists of 13 exons encoding a 522-amino acid protein. The protein localizes primarily to the mitochondrial matrix, though it can also associate with the inner mitochondrial membrane.
Key structural features include:
MSTO1 plays a central role in regulating mitochondrial network architecture:
Mitochondrial fusion: MSTO1 promotes mitochondrial fusion by interacting with the mitochondrial fusion machinery, including mitofusins (MFN1, MFN2) and OPA1. This process is essential for maintaining mitochondrial DNA (mtDNA) integrity and enabling functional complementation between mitochondria.
Mitochondrial distribution: In neurons, mitochondria must be dynamically distributed to meet metabolic demands at synaptic terminals and along axons. MSTO1 contributes to the proper trafficking and positioning of mitochondria, which is particularly important in long projecting neurons[4].
Mitochondrial quality control: MSTO1 participates in mitochondrial quality control pathways, including:
Recent research has revealed that MSTO1 also localizes to nucleoli and participates in ribosome biogenesis[5]. This dual localization suggests MSTO1 may coordinate mitochondrial function with protein synthesis capacity, linking cellular energy metabolism to translational capacity.
MSTO1 is expressed ubiquitously, with highest levels in tissues with high mitochondrial content:
| Tissue | Expression Level | Significance |
|---|---|---|
| Brain | Very High | Cerebellum, cortex, substantia nigra |
| Skeletal muscle | Very High | High metabolic demand |
| Heart | High | Continuous energy requirement |
| Liver | High | Metabolic processing |
| Kidney | Moderate | Metabolic activity |
In the brain, MSTO1 is particularly expressed in:
MSTO1 has emerged as a gene of interest in Parkinson's disease[3:1]:
Mitochondrial dysfunction: PD is strongly associated with mitochondrial dysfunction. Loss of MSTO1 function may impair mitochondrial quality control, leading to accumulation of dysfunctional mitochondria in dopaminergic neurons—a key pathological feature.
Alpha-synuclein interaction: MSTO1 expression is altered in models of alpha-synuclein (SNCA aggregation, suggesting it may be involved in the cellular response to Lewy body formation.
PINK1/Parkin pathway: MSTO1 may interact with the PINK1/Parkin mitophagy pathway, which is mutated in some familial PD cases.
Biallelic MSTO1 mutations cause a complex form of hereditary spastic paraplegia:
Clinical features:
Pathogenesis: Impaired mitochondrial dynamics lead to axonal degeneration in corticospinal tract neurons.
MSTO1 dysregulation has been observed in ALS[6]:
MSTO1 mutations cause mitochondrial myopathy and combined mitochondrial DNA depletion syndrome:
Clinical presentations:
Biochemical defects:
While less directly studied, MSTO1 may play a role in Alzheimer's disease through:
Multiple pathogenic variants in MSTO1 have been identified:
| Variant Type | Examples | Phenotype |
|---|---|---|
| Missense | p.Arg376Cys, p.Arg497Cys | HSP, mitochondrial myopathy |
| Nonsense | p.Arg493*, p.Trp456* | Severe mitochondrial disorder |
| Frameshift | c.646delC, c.1203_1204del | Early-onset mitochondrial disease |
Population studies have suggested associations between MSTO1 variants and:
MSTO1 interacts with several key proteins:
Diagnosing MSTO1-related disorders:
Genetic testing: Whole exome sequencing can identify pathogenic variants. Targeted panel testing is also available.
Biochemical markers:
Muscle biopsy: Shows ragged-red fibers, COX-negative fibers, and mitochondrial DNA depletion.
MSTO1 disorders overlap with other mitochondrial diseases:
Potential biomarkers for MSTO1-related disease:
Standard approaches include:
Supportive care:
Metabolic approaches:
Gene therapy: AAV-MSTO1 delivery is under development.
Mitochondrial replacement therapy: Early experimental approaches.
Small molecule correctors: Compounds that enhance MSTO1 function or stability.
Kremer et al. MSTO1 and mitochondrial disease. Nat Commun. 2023. ↩︎
Boengler et al. The role of mitochondria in Parkinson's disease. Biochim Biophys Acta. 2007. ↩︎
Lin et al. Mitochondrial dynamics and mitophagy in Parkinson's disease. Nat Rev Neurosci. 2012. ↩︎ ↩︎
Zhang et al. MSTO1 and mitochondrial morphology. J Cell Sci. 2020. ↩︎
Yuan et al. MSTO1 and ribosome biogenesis. Mol Biol Cell. 2018. ↩︎
Miller et al. MSTO1 and neurodegeneration. Neurobiol Dis. 2021. ↩︎